Cristin-resultat-ID: 1596548
Sist endret: 17. desember 2018 15:05
NVI-rapporteringsår: 2018
Resultat
Vitenskapelig artikkel
2018

Effect of anti-rheumatic treatment on selenium levels in inflammatory arthritis

Bidragsytere:
  • Gia Deyab
  • Ingrid Hokstad
  • Jan Aaseth
  • Milada Cvancarova Småstuen
  • Jon Elling Whist
  • Stefan Agewall
  • mfl.

Tidsskrift

Journal of Trace Elements in Medicine and Biology
ISSN 0946-672X
e-ISSN 1878-3252
NVI-nivå 1

Om resultatet

Vitenskapelig artikkel
Publiseringsår: 2018
Publisert online: 2018
Volum: 49
Sider: 91 - 97

Importkilder

Scopus-ID: 2-s2.0-85046819815

Beskrivelse Beskrivelse

Tittel

Effect of anti-rheumatic treatment on selenium levels in inflammatory arthritis

Sammendrag

Objectives: The reason for increased cardiovascular risk in inflammatory arthritis (IA) is unclear. Interestingly,selenium-deficiency is suspected to contribute to the development of cardiovascular disease (CVD) in the generalpopulation. Although the reference range of serum selenium (s-selenium) is 50–120 μg/L, there are indicationsthat levels up to 85 μg/L might not be sufficient for optimal cardioprotection. Our aim was to examine s-seleniumlevels in rheumatoid arthritis (RA), psoriatic arthritis (PsA) and ankylosing spondylitis (AS), to evaluate theeffect of anti-rheumatic treatment on s-selenium levels, and to assess relationships between s-selenium levels andclinical and laboratory parameters including markers of disease activity and CVD risk.Methods: We examined 64 patients with RA, 40 with PsA and 26 with AS starting with methotrexate (MTX)monotherapy or anti-tumor necrosis factor therapy (anti-TNF) with or without methotrexate (anti-TNF ± MTX)due to active disease. S-selenium, inflammatory biomarkers, endothelial function (EF) and other variables wereexamined at baseline and after 6 weeks and 6 months of treatment.Results: In the total IA group, s-selenium increased within 6 weeks of anti-rheumatic treatment, and thereafterthe levels remained stable until the end of the 6 months follow-up period. There were no significant differencesin s-selenium changes between the three diagnostic groups and between the two treatment regimens. Changes ins-selenium were negatively related to changes in C-reactive protein (CRP) and erythrocyte sedimentation rate(ESR), but there were no significant relationships to any other of the examined risk parameters for CVD includingEF.Conclusion: IA patients had s-selenium within the reference range, but below the level that might be necessaryfor optimal CVD protection.Anti-rheumatic treatment had a relatively rapid and sustained effect on s-selenium levels. The increase in s-selenium was related to reduction in inflammatory activity. In theory, anti-rheumatic drugs might improve s-selenium levels through inhibition of pro-inflammatory processes or through other mechanisms. Although wehave not revealed any significant relationships between s-selenium and CVD risk parameters, the role of sub-optimal s-selenium levels in pathogenesis of premature CVD in IA cannot be ruled out

Bidragsytere

Gia Deyab

  • Tilknyttet:
    Forfatter
    ved Div Medisinsk service ved Sykehuset Innlandet HF
Aktiv cristin-person

Ingrid Hokstad

  • Tilknyttet:
    Forfatter
    ved Revmatismesykehuset AS

Jan Olav Aaseth

Bidragsyterens navn vises på dette resultatet som Jan Aaseth
  • Tilknyttet:
    Forfatter
    ved Avd Forskning ved Sykehuset Innlandet HF
  • Tilknyttet:
    Forfatter
    ved Institutt for helse- og sykepleievitenskap ved Høgskolen i Innlandet

Milada Cvancarova Småstuen

  • Tilknyttet:
    Forfatter
    ved Institutt for sykepleie og helsefremmende arbeid ved OsloMet - storbyuniversitetet

Jon Elling Whist

  • Tilknyttet:
    Forfatter
    ved Avd Forskning ved Sykehuset Innlandet HF
  • Tilknyttet:
    Forfatter
    ved Div Medisinsk service ved Sykehuset Innlandet HF
1 - 5 av 11 | Neste | Siste »